Abstract
Background: The main aim of this work was to develop stable (>2 years) doxycycline formulation,
at clinically relevant concentrations and using clinically relevant formulation. Doxycycline has a
MMP- inhibitory effects that is important for the treatment of various oral mucosal conditions. Therefore,
protecting doxycycline from degradation in aqueous formulation requires halting or prevention of oxidation
and epimerisation of the active compound.
Methods: Stabilizing excipients were intuitively put together to enhance the stability as a cumulative effort.
A total of 30 hydrogels were compared with different types and concentrations of stability enhancing
excipients, pH, storage temperatures (4, 25 and 40°C) and mucoadhesive polymers. The duration of the
study was from day 1 and up to 58 months. The gelation temperature was adjusted below the actual body
temperature. The complexation efficiency between the doxycycline and HPβCD was studied using the
DSC, FTIR and XRPD.
Results: The majority of formulations at 4°C were highly stable by the end of 58 months and their stabilities
were improved at all 3 temperatures.
Conclusion: In conclusion, it is possible to prevent doxycycline from both oxidation and epimerization in
an aqueous formulation, for up to 5 years.
Keywords:
Stability, doxycycline, in situ, oral mucosal, drug delivery, mucoadhesive hydrogels.
Graphical Abstract
[1]
Scully C, Porter S. Recurrent aphthous stomatitis: current concepts of etiology, pathogenesis and management Journal of oral pathology & medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 1989; 18: 21-7.
[2]
Niharika Swain JPLSPYP. Niharika Swain, Etiological Factors of Recurrent Aphthous Stomatitis: A Common Perplexity - Review Articles 2012.
[12]
Abdulrahman Hani Sabbagh MFF. Therapeutic management of recurrent aphthous stomatitis: A review of the growing knowledge. Annals of International Medical and Dental Research 2016; 2
[14]
Hayrinen-Immonen R, Sorsa T, Pettila J, Konttinen YT, Teronen O, Malmstrom M. Malmstrom, Effect of tetracyclines on collagenase activity in patients with recurrent aphthous ulcers Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 1994; 23: 269-72.
[18]
Skulason S, Holbrook WP, Thormar H, Gunnarsson GB, Kristmundsdottir T. A study of the clinical activity of a gel combining monocaprin and doxycycline: a novel treatment for herpes labialis, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2012; 41: 61-7.
[21]
Abernethy J. A randomized, double-blind study to evaluate the safety and efficacy of NanoDOX™ 10% doxycycline monohydrate hydrogel in diabetic adult subjects with lower extremity ulcers compared to placebo hydrogel, Clinical connection, 2014.
[35]
Swati Rawat SW. Swaroop Lahoti In Situ Gel Formulation of Ornidazole for the Treatment of Periodontal Disease Current Pharma Research 2010; 1
[37]
Chang Y. Tetracycline stabilizing formulations. US Patent WO2010033800A22010.
[38]
Granatek AP. Tetracycline formulations stabilized by bisulfites. US Patent 3132993 1964.
[44]
Liu YR, Luhua YM. Qu, Yunzhi, Study on antiageing of doxycycline hydrochloride dropping pills. Heilongjiang Yiyao 2009; 22: 785-8.
[47]
Jenness R, Marth EH, Wong NP, Keeney M. Fundamentals of Dairy Chemistry. Springer 1988.